To Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of JMKX003142 Injection Administered Randomly, Double-blind, Placebo-controlled, Single-ascending Dose and Multiple-ascending Doses in Chinese Healthy Adult Subjects
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
78
JMKX003142 Injection will be administered intravenously once in SAD cohorts and once daily in MAD cohorts for 5 consecutive days.
Matching placebo will be administered intravenously once in SAD cohorts and once daily in MAD cohorts for 5 consecutive days.
Peking University Third Hospital
Beijing, Beijing Municipality, China
Number of the Adverse Events that are related to the single dose treatment
single dose safety single dose safety
Time frame: From Baseline to Day7
Number of the Adverse Events that are related to the multiple dose treatment
multiple dose safety multiple dose safety
Time frame: From Baseline to Day12
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.